P2-095: Prognostic value of the determination of K-ras mutations plasma in advanced non-small cell lung cancer (NSCLC) patients  by Sirera, Rafael et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS528
(MS) have not been reached either in ﬁrst- or second-line. However, 
when split according to methylation status, there was a trend toward 
better TTP and MS in both ﬁrst- and second-line in p with methylated 
14-3-3σ. TTP in second-line in p with methylated 14-3-3σ has not been 
reached, while it was 10.8 months (m) for p with unmethylated 14-3-3σ 
(P=ns). TTP in second-line in p with methylated CHFR was 5.2 m but 
was not reached for p with unmethylated CHFR (P=0.05). 
Conclusions: Methylated 14-3-3σ can permit Cbl binding to mutant 
EGFR and predict longer-lasting response to erlotinib in p with EGFR 
mutations. The precise role of CHFR warrants further research. Com-
plete data will be presented. 
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(NSCLC) patients
Sirera, Rafael1 Camps, Carlos1 Muñoz-Navarro, Mireia1 Blasco, Ana1 
Safont, María José1 Iranzo, Vega1 Baballero, Cristina1 de las Peñas, 
Ramón2 Tarón, Miquel3 Rosell, Rafael3 
1 Hospital General Universitario de Valencia, Valencia, Spain 2 Hospi-
tal Provincial de Castellón, Castellón, Spain 3 ICO, Hospital Germans 
Trias i Pujol, Badalona, Spain 
Background: Qualitative and quantitative analysis of circulating 
DNA in blood is a promising non-invasive diagnostic and prognostic 
tool. Our aim was to study the association between the free amount 
in plasma of the catalytic subunit of telomerase (hTERT) and several 
clinical variables in advanced NSCLC patients.
Methods: We examined 451 NSCLC patients in stage IIIB and IV, 
treated with cisplatin and docetaxel. Blood samples were collected be-
fore chemotherapy, and circulating DNA was extracted from the serum 
using commercial adsorption columns. The amount of free hTERT in 
plasma was quantiﬁed by using RT-PCR.
Results: Median age was 61 years [35-82] and 84% were males. 99% 
had performance status 0-1. 84% were in stage IV and 16% in stage 
IIIB. The histological subtypes were: 32% squamous cell carcinoma, 
50% adenocarcinoma, 14% anaplastic large cell, and 4% undifferen-
tiated. 41% of the patients received second line chemotherapy. 1% 
achieved complete response (CR), 36% partial response (PR), 35% had 
stable disease (SD) and 28% progressive disease (PD). Median hTERT 
value was 4856 ng/ml; for patients in IIIB was 48 ng/ml [2-9648] and 
48 ng/ml [0.6-43735] in stage IV (p=0.75). There was not association 
between hTERT values and response to therapy. hTERT values were 
not related with the localization of the metastasis. Dividing the cohort 
in two sets according to hTERT median we found two signiﬁcantly dif-
ferent groups in terms of Overall Survival (OS) and Time To Progres-
sion (TTP). Patients with hTERT <48 ng/ml had a median TTP of 5.3 
months (m) [4.4-6.1] while for hTERT >48 ng/ml was 4.1 m [3.5-4.6], 
(p=0.0009). OS when hTERT <48 ng/ml was 10.1m [4.9-11.3] and for 
hTERT >48 ng/ml was 8.4 m [7.2-9.5], (p=0.01). In the multivariate 
analysis, hTERT was an independent predictive variable for TTP (HR 
1.39, CI 95% 1.1-1.7, p=0.002) and OS (HR 1.27, CI 95% 1.1-1.6, 
p=0.04).
Conclusions: In advanced NSCLC patients, the quantiﬁcation of free 
circulating hTERT in plasma is an affordable and valuable prognostic 
marker. High plasma hTERT levels are a poor prognostic indicator for 
TTP and OS.
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Background: EGFR has an extracellular ligand-binding domain that 
can be proteolitically cleaved from the cell surface and can be accu-
rately quantiﬁed in blood by ELISA. We have investigated the useful-
ness of plasma EGFR measurements as prognostic marker in advanced 
NSCLC.
Methods: The cohort consisted in 329 patients (p) with advanced 
NSCLC that received ﬁrst-line therapy with cisplatin and docetaxel. 
The concentration levels of the EGFR extracellular binding domain 
were determined by a sandwich quantitative ELISA in the baseline, 
before therapy.
Results: Median age was 61, range [39-80], 84% males, 100% cau-
casian, 68% stage IIIB and 32% IV and 99% PS 0-1. The histological 
subtypes were: 31% squamous cell carcinoma, 49% adenocarcinoma, 
15% large cell, and 5% undifferentiated. 181 p achieved complete 
response (CR), partial response (PR) or stable disease (SD) and 109 
p progressive disease (PD). Median patient’s plasma levels of EGFR 
were 32.4 ng/ml. There were not differences in p according to histolo-
gy, site of metastasis and ECOG. There were differences in response to 
therapy; CR+PR+SD p presented median EGFR of 31.97 ng/ml [13.2-
48.6] vs 30 ng/ml [16.9-46.8] in the PD group (p=0.024). Dividing the 
cohort in two sets according to EGFR median we found two signiﬁ-
cantly different groups in terms of Overall Survival (OS) and Time To 
Progression (TTP). Patients with EGFR<32.4 ng/ml had a median TTP 
of 3.9 months (m) [3.3-4.6] while for EGFR>32.4 ng/ml was 4.7 m 
[4.0-5.4], (p=0.024). OS when EGFR<32.4 ng/ml was 6.9 m [5.9-7.8] 
and for EGFR>32.4 ng/ml was 9.1 m [8.2-10.1], (p=0.038).
Conclusions: Patients with PD presented signiﬁcantly lower levels of 
serum EGFR than those patients with CR+PR+SD. There is a relation-
ship among lower EGFR concentration in serum with a worst prognosis 
in advanced NSCLC p in terms of TTP and OS.
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Background: Qualitative analysis of circulating DNA in blood is a 
promising non-invasive diagnostic and prognostic tool. Our aim was to 
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study the association between the presence of K-ras mutations at codon 
12 and several clinical variables in advanced NSCLC patients.
Methods: We examined 451 NSCLC patients in stage IIIB and IV, 
treated with cisplatin and docetaxel. Blood samples were collected be-
fore chemotherapy, and circulating DNA was extracted from the plasma 
using commercial adsorption columns. K-ras mutational status was 
determined by a method based in allelic discrimination with RT-PCR.
Results: Median age was 61 years [35-82] and 84% were males. 99% 
had performance status 0-1. 84% were in stage IV and 16% in stage 
IIIB. The histological subtypes were: 32% squamous cell carcinoma, 
50% adenocarcinoma, 14% anaplastic large cell, and 4% undifferen-
tiated. 41% of the patients received second line chemotherapy. 1% 
achieved complete response (CR), 36% partial response (PR), 35% had 
stable disease (SD) and 28% progressive disease (PD). Here we pres-
ent the results of the analysis of K-ras mutations in the plasma of 165 
samples. 17 patients presented K-ras mutations (10.3%), being codon 
12 TGT in 16 patients and GTT in 1 case. Plasmatic mutations were 
found either in patients presenting squamous cell carcinoma (n=3) and 
in patients with adenocarcinoma (14). Patients with K-ras mutations in 
plasma had a median time to progression (TTP) of 2.3 months (m) [0.5-
4.6] while for wild type K-ras was 4.1 m [3.3-4.8], (p=0.9). Overall 
Survival (OS) in K-ras mutated patients was 10.1 m [4.1-15.8] and in 
wild type K-ras was 9.0 m [6.9-11.1], (p=0.6).
Conclusions: In advanced NSCLC, there were no signiﬁcant differ-
ences between patients with K-ras mutations and those with wild-type 
genotype with respect to baseline characteristics, response rates, TTP, 
or OS. Data from the rest of the cohort will be presented at the meeting.
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Background: VEGF and bFGF are among the most important an-
giogenic factors. We have explored these angiogenesis mediators in 
plasma and its prognostic signiﬁcance in advanced NSCLC.
Methods: Were enrolled 451 patients with advanced NSCLC, stages 
IIIB and IV and treated with cisplatin and docetaxel. Blood was col-
lected before chemotherapy. Plasma VEGF and bFGF levels were 
assessed by commercial ELISA (sensitivity 5 pg/ml). In parallel plasma 
from 32 age and gender-matched controls was used.
Results: Median age was 61 years (35-82) and 84% were males. 99% 
had performance status 0-1. 84% were in stage IV and 16% in stage 
IIIB. The histological subtypes were: 32% squamous cell carcinoma, 
50% adenocarcinoma, 14% anaplastic large cell, and 4% undifferen-
tiated. 41% of the patients received second line chemotherapy. 1% 
achieved complete response (CR), 36% partial response (PR), 35% had 
stable disease (SD) and 28% progressive disease (PD). Patient’s median 
plasma levels of VEGF (20 pg/ml, [6-203]) differ signiﬁcantly (p=0.04) 
from controls (14 pg/ml, [7-53]), but in contrast bFGF levels were not 
different, 14 pg/ml [5-960] vs 10 pg/ml [6-278] respectively. There 
were not differences in patients according to histology, site of metas-
tasis and ECOG; however we could observe a tendency with stage for 
both factors: bFGF 9 pg/ml [5-24] in stage IIIB vs 15 pg/ml [6-960], 
p=0.071 and VEGF 17 pg/ml [6-145] in IIIB vs 21 pg/ml [6-203] in 
IV, p=0.086. It could not be observed any differences in response to 
therapy for both angiogenic factors; CR+PR patients presented median 
VEGF of 18 pg/ml [6-71] and bFGF 11 pg/ml [6-960] vs 20 pg/ml of 
VEGF [6-203] and 15 pg/ml of bFGF [5-395] in the SD+PD group. 
In the multivariate analysis we could not ﬁnd that VEGF and bFGF 
plasma levels were predictors for time to progression (TTP) and overall 
survival (OS).
Conclusions: VEGF but not bFGF levels in patients are signiﬁcantly 
higher in patients than in controls. In our cohort of patients with 
advanced NSCLC we have not found any relationship between serum 
VEGF and bFGF levels with stage, histology, response, site of metasta-
sis, TTP and OS.
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Background: Platinum compounds and taxanes have severe side ef-
fects in a dose and time-dependent manner, especially neurotoxicity. 
NGF plays an important role in growth and differentiation of neuronal 
components. Our goal was to study NGF levels in plasma and correlate 
it with patient’s clinico-pathologic characteristics.
Methods: The study was performed with 451 patients with advanced 
NSCLC, stages IIIB-IV and treated with cisplatin and docetaxel. 
Peripheral blood was collected before therapy. NGF were assessed by 
commercial ELISA (detection limit, 5 pg/ml). Plasma from 32 age and 
gender-matched controls was used.
Results: 91% of males, mean age 61 y [35-82]. 86 patients in ECOG 
PS 0-1 and 14 PS2. 71% in stage IV and 29% in IIIB. The histological 
subtypes were 38% squamous cell, 37% adenocarcinoma, 5% anaplasic 
large cell and 20% undifferentiated. 77.5% of the metastasis was out of 
the lung. Patients received a median of 6 cycles of chemotherapy [1-7]. 
4% presented complete response (CR), 38% partial response (PR), 25% 
stable disease (SD) and 30% progressive disease (PD). Patient’s median 
plasma levels of NGF did not differ signiﬁcantly from controls: 44 
pg/ml [6-176] vs 31 pg/ml [14-144] respectively. There were not dif-
ferences according to histology, site of metastasis and ECOG; however 
we could observe signiﬁcant differences with stage: 25 pg/ml [10-70] 
in stage IIIB vs 47 pg/ml [6-176] in stage IV (p=0.008). We could 
not observe any differences in response to therapy: CR+PR patients 
presented median NGF of 35 pg/ml [6-92] vs 39 pg/ml [10-165] in the 
SD+PD group. Splitting the cohort according to NGF median we found 
two signiﬁcantly different groups in terms of Overall Survival (OS): 
patients with NGF<44 pg/ml had a median OS of 10.9 months (m) 
[7.9-13.9] vs 7.3 m [3-11.5] for patients with NGF>44 pg/ml (p=0.03). 
In the multivariate analysis, NGF levels was not predictor for time to 
progression (TTP) and OS.
